Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
This fusion RNA, SLC45A3-ELK4, generated by cis-splicing between neighboring genes, was found in prostate cancer.
|
28716526 |
2017 |
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
The chimeric transcript, but not wild-type ELK4, is shown to augment prostate cancer cell proliferation.
|
22787087 |
2012 |
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
Several studies have assessed the rearrangement status of the most commonly found ETS rearranged gene ERG, and the less frequent genes, ETV-1, ETV-4, ETV-5, and ELK-4 in primary prostate cancer.
|
22569213 |
2012 |
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
With the absence of corresponding DNA rearrangement, chimeric fusion SLC45A3-ELK4 transcript in prostate cancer cells is generated by cis-splicing of adjacent genes/gene read-through instead of trans-splicing.
|
22719019 |
2012 |
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Recently, a SLC45A3-ELK4 chimera has been shown to be androgen-regulated, and is overexpressed in metastatic or high-grade prostate tumors relative to local prostate cancers.
|
20406994 |
2010 |
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
SLC45A3-ELK4 transcript can be detected at high levels in urine samples from men at risk for prostate cancer.
|
19293179 |
2009 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
This fusion RNA, SLC45A3-ELK4, generated by cis-splicing between neighboring genes, was found in prostate cancer.
|
28716526 |
2017 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Several studies have assessed the rearrangement status of the most commonly found ETS rearranged gene ERG, and the less frequent genes, ETV-1, ETV-4, ETV-5, and ELK-4 in primary prostate cancer.
|
22569213 |
2012 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The chimeric transcript, but not wild-type ELK4, is shown to augment prostate cancer cell proliferation.
|
22787087 |
2012 |
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
With the absence of corresponding DNA rearrangement, chimeric fusion SLC45A3-ELK4 transcript in prostate cancer cells is generated by cis-splicing of adjacent genes/gene read-through instead of trans-splicing.
|
22719019 |
2012 |
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
SLC45A3-ELK4 transcript can be detected at high levels in urine samples from men at risk for prostate cancer.
|
19293179 |
2009 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Tumor expression of neither ELK3 nor ELK4 was associated with disease-free survival (DFS).
|
31794091 |
2020 |
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The strongest signal maps to a transcriptional enhancer element in which the G allele of the best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors.
|
23540573 |
2013 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Furthermore, in vivo, ELK4 downregulation reduced tumor formation in glioblastoma xenograft models.
|
21846680 |
2011 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Altogether, these results indicate that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein.
|
28716526 |
2017 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Altogether, these results indicate that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein.
|
28716526 |
2017 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Although the expression level of SLC45A3-ELK4 is higher in cancer than normal cells, and a dramatic increase in its expression from normal to cancer cells is correlated with advanced disease, its expression level in cancer samples alone is not correlated with any clinical parameters.
|
25188740 |
2014 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Although the expression level of SLC45A3-ELK4 is higher in cancer than normal cells, and a dramatic increase in its expression from normal to cancer cells is correlated with advanced disease, its expression level in cancer samples alone is not correlated with any clinical parameters.
|
25188740 |
2014 |
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Recently, a SLC45A3-ELK4 chimera has been shown to be androgen-regulated, and is overexpressed in metastatic or high-grade prostate tumors relative to local prostate cancers.
|
20406994 |
2010 |
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells.
|
18469865 |
2008 |
Oral candidiasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
SAP1 and SAP3 transcripts were observed only in patients with oral candidiasis.
|
10225911 |
1999 |
Oral candidiasis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of SAP1-3 and 6 was also detected by RT-PCR in samples from patients suffering from oral candidosis.
|
9720876 |
1998 |
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In total, 14 DEMs were found in CRC.By bioinformatics analysis, 5 DEMs (miR-145, miR-497, miR-30a, miR-31, and miR-20a) and 8 TFs (ELK4 (ETS-family transcription factor), myeloblastosis proto-oncogene like (MYBL)1, MYBL2, CEBPA, PPARA, PPARD, PPARG, and endothelial PAS domain protein (EPAS1)) appeared to be associated with CRC and were therefore used to construct miRNA-TF-gene networks.
|
30985693 |
2019 |
Early childhood caries
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, secreted aspartic protease (Sap) activity and SAP1-5 transcriptional levels were compared in the ECC and caries-free (CF) groups of Uygur children.
|
30518349 |
2018 |
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, ELK4 is overexpressed in melanoma and knocking down the ELK4 or CDK2 expression significantly attenuated the malignant phenotype of melanoma cells.
|
26028036 |
2016 |